<DOC>
	<DOCNO>NCT01405261</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability pharmacokinetics ( exposure trial drug body ) single dos NNC 0113-0987 healthy male subject .</brief_summary>
	<brief_title>Trial Investigating Safety NNC 0113-0987 Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male subject good general health judge investigator , base medical history , physical examination include 12lead electrocardiogram ( ECG ) , vital sign , blood urinary laboratory assessment screen visit Body Mass Index ( BMI ) minimum 18.5 30 kg/m^2 Male subject sexually active surgically sterilise , whose partner unwilling use two different form effective contraception , one barrier method ( e.g . condom spermicidal foam/gel/film/cream ) duration trial 3 month follow last dose trial medication The receipt investigational product within 90 day ( 5 halflives investigational drug , whichever great ) prior trial ( screen ) , currently enrol clinical trial Subjects history presence cancer , diabetes , clinically significant cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , haematological , dermatological , venereal , neurological , psychiatric disease major disorder might impact current trial , judge investigator Subjects know hepatitis carrier Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody , positive result test Human Immunodeficiency Virus ( HIV ) antibodies History chronic idiopathic acute pancreatitis amylase lipase value 3x upper normal range ( UNR )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>